Enhanced T-cell Immunogenicity and Protective Efficacy of a Human Immunodeficiency Virus Type 1 Vaccine Regimen Consisting of Consecutive Priming with DNA and Boosting with Recombinant Fowlpox Virus

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 1998 Nov 13

PMID 9811759

Citations 79

Authors

S J Kent

A Zhao

S J Best

J D Chandler

D B Boyle

I A Ramshaw

Affiliations

Soon will be listed here.

Abstract

The induction of human immunodeficiency virus (HIV)-specific T-cell responses is widely seen as critical to the development of effective immunity to HIV type 1 (HIV-1). Plasmid DNA and recombinant fowlpox virus (rFPV) vaccines are among the most promising safe HIV-1 vaccine candidates. However, the immunity induced by either vaccine alone may be insufficient to provide durable protection against HIV-1 infection. We evaluated a consecutive immunization strategy involving priming with DNA and boosting with rFPV vaccines encoding common HIV-1 antigens. In mice, this approach induced greater HIV-1-specific immunity than either vector alone and protected mice from challenge with a recombinant vaccinia virus expressing HIV-1 antigens. In macaques, a dramatic boosting effect on DNA vaccine-primed HIV-1-specific helper and cytotoxic T-lymphocyte responses, but a decline in HIV-1 antibody titers, was observed following rFPV immunization. The vaccine regimen protected macaques from an intravenous HIV-1 challenge, with the resistance most likely mediated by T-cell responses. These studies suggest a safe strategy for the enhanced generation of T-cell-mediated protective immunity to HIV-1.

Citing Articles

The Development of Methods for the Production of New Molecular Vaccines and Appropriate RNA Fragments to Counteract Unwanted Genes: A Pilot Study.

Sainova I, Kolyovska V, Ilieva I, Markova T, Dimitrova-Dikanarova D, Hadjiolova R Vaccines (Basel). 2023; 11(7).

PMID: 37515042 PMC: 10386085. DOI: 10.3390/vaccines11071226.

Virus-Like Particles Are Efficient Tools for Boosting mRNA-Induced Antibodies.

Vogt A, Jorg L, Martina B, Krenger P, Chang X, Zeltins A Front Immunol. 2022; 13:864718.

PMID: 35784292 PMC: 9245429. DOI: 10.3389/fimmu.2022.864718.

Viral Vector Vaccines against Bluetongue Virus.

Jimenez-Cabello L, Utrilla-Trigo S, Calvo-Pinilla E, Moreno S, Nogales A, Ortego J Microorganisms. 2020; 9(1).

PMID: 33375723 PMC: 7823852. DOI: 10.3390/microorganisms9010042.

Chimeric Virus-Like Particles and Capsomeres Induce Similar CD8 T Cell Responses but Differ in Capacity to Induce CD4 T Cell Responses and Antibody Responses.

Pattinson D, Apte S, Wibowo N, Rivera-Hernandez T, Groves P, Middelberg A Front Immunol. 2020; 11:564627.

PMID: 33133076 PMC: 7550421. DOI: 10.3389/fimmu.2020.564627.

Vaccine Design Informed by Virus-Induced Immunity.

Penkert R, Hankins J, Young N, Hurwitz J Viral Immunol. 2020; 33(4):342-350.

PMID: 32366204 PMC: 7247049. DOI: 10.1089/vim.2019.0138.

References

Fazekas de St Groth . The evaluation of limiting dilution assays. J Immunol Methods. 1982; 49(2):R11-23. DOI: 10.1016/0022-1759(82)90269-1. View

Salk J, Bretscher P, Salk P, Clerici M, Shearer G . A strategy for prophylactic vaccination against HIV. Science. 1993; 260(5112):1270-2. DOI: 10.1126/science.8098553. View

Koup R, Safrit J, Cao Y, Andrews C, McLeod G, Borkowsky W . Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 1994; 68(7):4650-5. PMC: 236393. DOI: 10.1128/JVI.68.7.4650-4655.1994. View

Stott E . Towards a vaccine against AIDS: lessons from simian immunodeficiency virus vaccines. Curr Top Microbiol Immunol. 1994; 188:221-37. DOI: 10.1007/978-3-642-78536-8_12. View

Leong K, Ramsay A, Boyle D, Ramshaw I . Selective induction of immune responses by cytokines coexpressed in recombinant fowlpox virus. J Virol. 1994; 68(12):8125-30. PMC: 237277. DOI: 10.1128/JVI.68.12.8125-8130.1994. View

Daniel M, Mazzara G, Simon M, Sehgal P, Kodama T, Panicali D . High-titer immune responses elicited by recombinant vaccinia virus priming and particle boosting are ineffective in preventing virulent SIV infection. AIDS Res Hum Retroviruses. 1994; 10(7):839-51. DOI: 10.1089/aid.1994.10.839. View

Kent S, Corey L, Agy M, Morton W, McElrath M, Greenberg P . Cytotoxic and proliferative T cell responses in HIV-1-infected Macaca nemestrina. J Clin Invest. 1995; 95(1):248-56. PMC: 295418. DOI: 10.1172/JCI117647. View

Baba T, Jeong Y, Pennick D, Bronson R, Greene M, Ruprecht R . Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science. 1995; 267(5205):1820-5. DOI: 10.1126/science.7892606. View

Nakanishi K, Yoshimoto T, Chu C, Matsumoto H, Hase K, Nagai N . IL-2 inhibits IL-4-dependent IgE and IgG1 production in vitro and in vivo. Int Immunol. 1995; 7(2):259-68. DOI: 10.1093/intimm/7.2.259. View

10.

Lu S, SANTORO J, Fuller D, Haynes J, Robinson H . Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice. Virology. 1995; 209(1):147-54. DOI: 10.1006/viro.1995.1238. View

11.

Egan M, Pavlat W, Tartaglia J, Paoletti E, Weinhold K, Clements M . Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene. J Infect Dis. 1995; 171(6):1623-7. DOI: 10.1093/infdis/171.6.1623. View

12.

Walter E, Greenberg P, Gilbert M, Finch R, Watanabe K, Thomas E . Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995; 333(16):1038-44. DOI: 10.1056/NEJM199510193331603. View

13.

Rowland-Jones S, Sutton J, Ariyoshi K, Dong T, Gotch F, McAdam S . HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med. 1995; 1(1):59-64. DOI: 10.1038/nm0195-59. View

14.

Gallimore A, Cranage M, Cook N, Almond N, Bootman J, Rud E . Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques. Nat Med. 1995; 1(11):1167-73. DOI: 10.1038/nm1195-1167. View

15.

Sonza S, Maerz A, Deacon N, Meanger J, Mills J, Crowe S . Human immunodeficiency virus type 1 replication is blocked prior to reverse transcription and integration in freshly isolated peripheral blood monocytes. J Virol. 1996; 70(6):3863-9. PMC: 190263. DOI: 10.1128/JVI.70.6.3863-3869.1996. View

16.

Lu S, Arthos J, Montefiori D, Yasutomi Y, Manson K, Mustafa F . Simian immunodeficiency virus DNA vaccine trial in macaques. J Virol. 1996; 70(6):3978-91. PMC: 190276. DOI: 10.1128/JVI.70.6.3978-3991.1996. View

17.

Kent S, Hu S, Corey L, Morton W, Greenberg P . Detection of simian immunodeficiency virus (SIV)-specific CD8+ T cells in macaques protected from SIV challenge by prior SIV subunit vaccination. J Virol. 1996; 70(8):4941-7. PMC: 190445. DOI: 10.1128/JVI.70.8.4941-4947.1996. View

18.

Kent S, Clancy R, Ada G . Managing HIV. Part 8: Controlling an epidemic. 8.3 Prospects for a preventive HIV vaccine. Med J Aust. 1996; 165(4):212-5. View

19.

Sharma D, Ramsay A, Maguire D, Rolph M, Ramshaw I . Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo. J Virol. 1996; 70(10):7103-7. PMC: 190762. DOI: 10.1128/JVI.70.10.7103-7107.1996. View

20.

Fleury B, Janvier G, Pialoux G, Buseyne F, Robertson M, Tartaglia J . Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp 160 of HIV-1 and boosted with a recombinant gp160. J Infect Dis. 1996; 174(4):734-8. DOI: 10.1093/infdis/174.4.734. View